IHAM
ITCI

Integral Health Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Integral Health Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100,000
Closed -$2.57M – 87
2020
Q2 		$2.57M Buy
+100,000
New +$2.02M 0.77% 47

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Integral Health Asset Management's ITCI Position: Q3 2024 in Review

Integral Health Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 145,000 shares — an estimated $9.93M sold.

Integral Health Asset Management first reported a position in ITCI in Q3 2020 and held it in 9 quarters. The position peaked at $12.5M in Q4 2023. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Integral Health Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Integral Health Asset Management sold 145,000 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $9.93M.
  • Integral Health Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 9 quarters.
  • Integral Health Asset Management's Intra-Cellular Therapies Inc. position peaked at $12.5M in Q4 2023.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Integral Health Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.